Log In Sign up
The largest database of trusted experimental protocols

N benzylbenzamide

Manufactured by Merck Group
Visit Supplier
Sourced in United States, Sao Tome and Principe

N-benzylbenzamide is a chemical compound that can be used as a laboratory reagent. It has the molecular formula C14H13NO. The compound is a white solid at room temperature.

Automatically generated - may contain errors

Lab products found in correlation

Prominence lc, by Shimadzu (4 mentions) Ondansetron hydrochloride, by Merck Group (2 mentions) 4000 qtrap, by Shimadzu (2 mentions) 3200 qtrap, by Shimadzu (2 mentions) Xdb c18 column, by Agilent Technologies (2 mentions) Tolbutamide, by Merck Group (2 mentions) 4000qtrap mass spectrometer, by Shimadzu (2 mentions) Agilent xdb c18 column, by Agilent Technologies (2 mentions) Tariquidar, by Merck Group (1 mentions) K3edta, by Merck Group (1 mentions)

6 protocols using n benzylbenzamide

1

Analytical Procedures for Drug Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tariquidar (CAS: 206873–63-4), ondansetron hydrochloride (CAS: 103639–04-9), N-benzylbenzamide (CAS: 1485–70-7) and ethylenediaminetetraacetic acid tripotassium (K3EDTA, CAS: 65501–24-8) were obtained from Sigma-Aldrich (St. Louis, MO). Pooled human and rat plasma were from BioIVT (Westbury, NY). All solvents used in the study were HPLC grade or higher and were purchased from Fisher Scientific (Fair Lawn, NJ).
Chong Y.E., Chiang M., Deshpande K., Haroutounian S., Kagan L, & Lee J.B. (2019). Simultaneous quantification of ondansetron and tariquidar in rat and human plasma using HPLC-UV. Biomedical chromatography : BMC, 33(11), e4653.
+ Open protocol
+ Expand
2

Quantitative LC-MS/MS Bioanalysis of Compound 13

Check if the same lab product or an alternative is used in the 5 most similar protocols
Levels of analog 13 for in vitro and in vivo pharmacology assays were monitored by LC-MS/MS using an AB Sciex (Framingham, MA) 3200 Q.TRAP® or 4000 Q.TRAP® mass spectrometer coupled to a Shimadzu (Columbia, MD) Prominence LC. The compound was detected with the mass spectrometer in positive MRM (multiple reaction monitoring) mode by following the precursor to fragment ion transition 470.1/360.1. The cleanest results were obtained using the parent mass composed of a 35Cl and a 37Cl (m+1). An Agilent C18 XDB column (5 micron, 50 X 4.6 mm) was used for chromatography with the following conditions: Buffer A: dH20 + 0.1% formic acid + 2 mM NH4 acetate, Buffer B: methanol + 0.1% formic acid + 2 mM NH4 acetate, 0 - 1.5 min 3% B, 1.5 – 2.5 min gradient to 100% B, 2.5 - 3.5 min 100% B, 3.5 - 3.6 min gradient to 3% B, 3.6 - 4.5 3% B. N-benzylbenzamide (transition 212.1 to 91.1 from Sigma (St. Louis, MO) was used as an internal standard (IS).
Nguyen T.P., Wang W., Sternisha A.C., Corley C.D., Wang H.Y., Wang X., Ortiz F., Lim S.K., Abdullah K.G., Parada L.F., Williams N.S., McBrayer S.K., McDonald J.G., De Brabander J.K, & Nijhawan D. (2023). Selective and brain-penetrant lanosterol synthase inhibitors target glioma stem-like cells by inducing 24(S),25-epoxycholesterol production. Cell chemical biology, 30(2), 214-229.e18.
+ Open protocol
+ Expand
3

Metabolic Stability and PK Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
SW208108, dMe-SW208108 and SW203668 compound levels for metabolic stability and pharmacokinetic studies were monitored by LC-MS/MS using an AB Sciex (Framingham, MA) 4000 Qtrap mass spectrometer coupled to a Shimadzu (Columbia, MD) Prominence LC. All three analytes were detected with the mass spectrometer in positive MRM (multiple reaction monitoring) mode by following the precursor to fragment ion transition 457.186 to 135.1 for SW208108, 443.252 to 121.0 for dMe-SW208108 and 390.13 to 210.1 for SW203668. An Agilent C18 XDB column (5 micron, 50 × 4.6 mm) was used for chromatography for all three compounds with the following conditions: Buffer E: dH20 + 0.1% formic acid, Buffer F: methanol + 0.1% formic acid, 0–1.5 min 3% F, 1.5 – 2 min gradient to 100% F, 2 – 3.2 min 100% B, 3.2 – 3.5 min gradient to 3% F, 3.5 – 4.5 3%. N-benzylbenzamide (transition 212.1 to 91.1) or tolbutamide (transition 271.2 t0 91.2) both from Sigma (St. Louis, MO) were used as internal standards (IS).
Theodoropoulos P.C., Gonzales S.S., Winterton S.E., Rodriguez-Navas C., McKnight J.S., Morlock L.K., Hanson J.M., Cross B., Owen A.E., Duan Y., Moreno J.R., Lemoff A., Mirzaei H., Posner B.A., Williams N.S., Ready J.M, & Nijhawan D. (2016). Discovery of Tumor-Specific Irreversible Inhibitors of Stearoyl CoA Desaturase. Nature chemical biology, 12(4), 218-225.
+ Open protocol
+ Expand
4

Metabolic Stability and PK Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
SW208108, dMe-SW208108 and SW203668 compound levels for metabolic stability and pharmacokinetic studies were monitored by LC-MS/MS using an AB Sciex (Framingham, MA) 4000 Qtrap mass spectrometer coupled to a Shimadzu (Columbia, MD) Prominence LC. All three analytes were detected with the mass spectrometer in positive MRM (multiple reaction monitoring) mode by following the precursor to fragment ion transition 457.186 to 135.1 for SW208108, 443.252 to 121.0 for dMe-SW208108 and 390.13 to 210.1 for SW203668. An Agilent C18 XDB column (5 micron, 50 × 4.6 mm) was used for chromatography for all three compounds with the following conditions: Buffer E: dH20 + 0.1% formic acid, Buffer F: methanol + 0.1% formic acid, 0–1.5 min 3% F, 1.5 – 2 min gradient to 100% F, 2 – 3.2 min 100% B, 3.2 – 3.5 min gradient to 3% F, 3.5 – 4.5 3%. N-benzylbenzamide (transition 212.1 to 91.1) or tolbutamide (transition 271.2 t0 91.2) both from Sigma (St. Louis, MO) were used as internal standards (IS).
Theodoropoulos P.C., Gonzales S.S., Winterton S.E., Rodriguez-Navas C., McKnight J.S., Morlock L.K., Hanson J.M., Cross B., Owen A.E., Duan Y., Moreno J.R., Lemoff A., Mirzaei H., Posner B.A., Williams N.S., Ready J.M, & Nijhawan D. (2016). Discovery of Tumor-Specific Irreversible Inhibitors of Stearoyl CoA Desaturase. Nature chemical biology, 12(4), 218-225.
+ Open protocol
+ Expand
5

Quantification of Ondansetron in Rat Biosamples

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ondansetron hydrochloride, N-benzylbenzamide, ethylenediaminetetraacetic acid tripotassium (K3EDTA) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Pooled male rat plasma and cerebrospinal fluid was purchased from BioIVT (Westbury, NY, USA). All solvents were of HPLC or higher grade and were purchased from Fisher Scientific (Fair Lawn, NJ, USA).
Chiang M., Back H.M., Bong Lee J., Oh S., Guo T., Girgis S., Park C., Haroutounian S, & Kagan L. (2020). Pharmacokinetic modeling of the impact of P-glycoprotein on ondansetron disposition in the central nervous system. Pharmaceutical research, 37(10), 205.
+ Open protocol
+ Expand
6

LC-MS/MS Quantitation of Pharmacological Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
Compound levels for in vitro and in vivo pharmacology assays were monitored by LC-MS/MS using an AB Sciex (Framingham, MA) 3200 QTRAP® or 4000 QTRAP® mass spectrometer coupled to a Shimadzu (Columbia, MD) Prominence LC. Analytes were detected with the mass spectrometer in positive MRM (multiple reaction monitoring) mode by following the precursor to fragment ion transition for two daughter ions. Only one parent daughter pair, indicated here, was used for quantitation: 40: 368.100/283.000; 48: 385.300/300.000; 49: 399.123/314.1; 43: 369.300/257.500; 44: 369.300/258.000. An Agilent C18 XDB column (5 micron, 50 X 4.6 mm) was used for chromatography for 40 and 49 with the following conditions: Buffer A: dH20 + 0.1% formic acid, Buffer B: methanol + 0.1% formic acid, 0 - 1.5 min 3% B, 1.5 - 2 min gradient to 100% B, 2 - 3.5 min 100% B, 3.5 - 3.6 min gradient to 3% B, 3.6 - 4.5 3% B. N-benzylbenzamide (transition 212.1 to 91.1 from Sigma (St. Louis, MO) was used as an internal standard (IS). Evaluation of other compounds employed nearly identical conditions except the gradient utilized was 0 - 1.0 min 3% B, 1.0 – 2 min gradient to 100% B, 2.0- 3.5 min 100% B, 3.5 - 3.6 min gradient to 3% B, 3.6 - 4.5 3% B.
Hu B., Toda K., Wang X., Antczak M., Smith J., Geboers S., Nishikawa G., Li H., Dawson D., Fink S., Desai A., Williams N.S., Markowitz S.D, & Ready J.M. (2022). Orally bioavailable quinoxaline inhibitors of 15-prostaglandin dehydrogenase (15-PGDH) promote tissue repair and regeneration. Journal of medicinal chemistry, 65(22), 15327-15343.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!